Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin

Journal of Immunotherapy

Volumn 30, Issue 2, 2007, Pages 227-233

  Russell, Heidi V ^a,g   Strother, Douglas ^a,c   Mei, Zhuyong ^b   Rill, Donna ^b,d   Popek, Edwina ^a   Biagi, Ettore ^b,e   Yvon, Eric ^b   Brenner, Malcolm ^b   Rousseau, Raphael ^b,f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

^d PharmaFrontiers Corp   (United States)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f CENTRE LÉON BÉRARD   (France)

^g TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Gene therapy; Neuroblastoma; Phase I; Vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5; LYMPHOTACTIN; TUMOR CELL VACCINE;

ADOLESCENT; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; EOSINOPHIL; ERYTHEMA; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHOCYTIC INFILTRATION; MALE; METABOLIC DISORDER; MOLECULAR RECOGNITION; MYALGIA; NAUSEA; NEUROBLASTOMA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN INDURATION; SWELLING; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; CANCER VACCINES; CELL LINE, TUMOR; CHILD; FEMALE; GENETIC ENGINEERING; HUMANS; INTERLEUKIN-2; LYMPHOKINES; MALE; NEUROBLASTOMA; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; SIALOGLYCOPROTEINS; TREATMENT OUTCOME; VACCINATION;

EID: 34247561214     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211335.14385.57     Document Type: Article

References (17)

1. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2:1090-1095.
2. Rousseau RF, Brenner MK. Vaccine therapies for pediatric malignancies. Cancer J. 2005;11:331-339.
3. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949.
4. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998;9:1303-1311.
5. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101:1718-1726.
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
7. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol. 1983;130:2471-2478.
8. Wolfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54:400-406.
9. Airoldi I, Lualdi S, Bruno S, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Br J Cancer. 2003;88:1527-1536.
10. Sakai K, Li Y, Shirakawa T, et al. Induction of major histocompatibility complex class I molecules on human neuroblastoma line cells by a flavoid antioxidant. Neurosci Lett. 2001;298:127-130.
11. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005;24:4634-4644.
12. Murphy C, Nikodem D, Howcroft K, et al. Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem. 1996;271:30992-30999.
13. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997;8:1935-1943.
14. Sarkar AK, Burlingame SM, Zang YQ, et al. Major histocompatibility complex-restricted lysis of neuroblastoma cells by autologous cytotoxic T lymphocytes. J Immunother. 2001;24:305-311.
15. Stievano L, Piovan E, Amadori A. C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol. 2004;24:205-228.
16. Mocellin S, Mandruzzato S, Bronte V, et al. Part I: vaccines for solid tumours. Lancet Oncol. 2004;5:681-689.
17. Kushner B, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monocolonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189-4194.